Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose SB681323 vs prednisolone vs placebo in rheumatoid arthritis (CRP response)
2004-005115-29Phase 2Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dilmapimod in rheumatoid arthritis (RA) (3 arms), sponsored by GSK. Primary endpoint: C-reactive protein level at 72 hours post-dose. Started May 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-005115-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005115-29.